Fusion Pharmaceuticals Inc. (FUSN) |
|
2.75 0.02 (0.73%)
|
06-26 19:51 |
|
Open: |
3.05 |
Pre. Close: |
2.73 |
|
High:
|
3.05 |
Low:
|
2.64 |
|
Volume:
|
59,163 |
Market Cap:
|
119(M) |
|
|
|
|
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.05 - 3.07 |
3.07 - 3.08 |
|
Low:
|
2.61 - 2.62 |
2.62 - 2.64 |
|
Close:
|
2.73 - 2.75 |
2.75 - 2.77 |
|
Technical analysis |
as of: 2022-06-24 4:40:08 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 4.11  One year: 4.75 |
| Support: |
Support1: 2.64 Support2: 2.19 |
| Resistance: |
Resistance1: 3.52 Resistance2: 4.07 |
| Pivot: |
3.4 |
| Moving Average: |
MA(5): 3.04 MA(20): 3.45
MA(100): 5.86 MA(250): 6.66 |
| MACD: |
MACD(12,26): -0.4 Signal(9): -0.4 |
| Stochastic oscillator: |
%K(14,3): 5.1  %D(3): 5.3 |
| RSI: |
RSI(14): 14.1 |
| 52-week: |
High: 9.5 Low: 2.64 |
| Average Vol(K): |
3-Month: 18 (K) 10-Days: 27 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ FUSN ] has closed below the lower bollinger band by 1.5%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ FUSN ] is to continue within current trading range. Bollinger Bands are 10% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Sun, 26 Jun 2022
Mobile E-Commerce Software Market Booming Worldwide With Leading Key Players -Shopgate, Shopify Mobile App Builder, Moltin, Branding Brand, Elastic Path, Knowband, AmazingCart, Apptuse Go, Contus, Dynamicweb, Elite mCommerce, exporthub, Fus - Indian Defence News
Thu, 23 Jun 2022
Fusion Pharmaceuticals Inc (FUSN) Stock Falls -15.43% This Week; Should You Buy? - InvestorsObserver
Thu, 23 Jun 2022
Health Care Sector Update for 06/23/2022: FSTX, FUSN, AMYT, XLV, IBB - Nasdaq
Thu, 23 Jun 2022
Fusion Pharmaceuticals Inc. (FUSN) Announces FDA Clearance of IND for FPI-2059 - StreetInsider.com
Tue, 21 Jun 2022
FUSION PHARMACEUTICALS INC. : Submission of Matters to a Vote of Security Holders (form 8-K) - Marketscreener.com
Fri, 10 Jun 2022
Fusion Pharmaceuticals (FUSN) Stock Price: Why It Increased Over 4% Today - Pulse 2.0
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
43 (M) |
|
% Held by Insiders
|
2.318e+007 (%) |
|
% Held by Institutions
|
8.4 (%) |
|
Shares Short
|
73 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-8.413e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-4 |
|
Return on Assets (ttm)
|
190.6 |
|
Return on Equity (ttm)
|
-19.9 |
|
Qtrly Rev. Growth
|
2.02e+006 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0.01 |
|
EBITDA (p.s.)
|
-1.76 |
|
Qtrly Earnings Growth
|
-2 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-70 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
140 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
80780 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
